Details of the Drug

General Information of Drug (ID: DM8JXPZ)

Drug Name

Glibenclamide

Synonyms

Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Non-insulin dependent diabetes	5A11	Approved	[2]
Stroke	8B20	Phase 3	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

494

Logarithm of the Partition Coefficient (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 348 mcgh/L [4]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 211-315 mcg/L [4]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.9-1.0 h [4]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability: 82% of drug becomes completely available to its intended biological destination(s) [6]
Clearance: The clearance of drug is 2.70-3.55 L/h [4]
Elimination: 50% of drug is excreted in the urine and 50% in the feces [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.0 - 13.4 hours [4]
Metabolism: The drug is metabolized via the CYP3A4, followed by CYP2C9, CYP2C19, CYP3A7, and CYP3A5 [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.57836 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.021% [10]
Vd: The volume of distribution (Vd) of drug is 21.5-49.3 L [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.004 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Haemolysis	Not Available	G6PD	OT300SMK	[11]
-----------

Chemical Identifiers

Formula: C23H28ClN3O5S
IUPAC Name: 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
Canonical SMILES: COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI: InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
InChIKey: ZNNLBTZKUZBEKO-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3488
ChEBI ID: CHEBI:5441
CAS Number: 10238-21-8
DrugBank ID: DB01016
TTD ID: D05LYX
VARIDT ID: DR00094
INTEDE ID: DR0775
ACDINA ID: D00304

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Modulator	[12]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[14]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[16]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[17]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[18]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[19]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[19]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[20]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[21]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[21]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[21]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[22]
ATP-sensitive inward rectifier potassium channel 8 (KCNJ8)	OTZ8G8FE	KCNJ8_HUMAN	Gene/Protein Processing	[23]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[24]
Calpain-2 catalytic subunit (CAPN2)	OTIAPE5J	CAN2_HUMAN	Gene/Protein Processing	[25]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[25]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[25]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Glibenclamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Glibenclamide due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[26]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[27]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Glibenclamide due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[28]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Oxymetholone.	Aplastic anaemia [3A70]	[29]
Clarithromycin	DM4M1SG	Moderate	Increased plasma concentration of Glibenclamide and Clarithromycin due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[30]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[31]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Glibenclamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[29]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[29]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Glibenclamide and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[33]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Glibenclamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[34]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Glibenclamide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[35]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Sertraline.	Depression [6A70-6A7Z]	[29]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Vilazodone.	Depression [6A70-6A7Z]	[29]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Selegiline.	Depression [6A70-6A7Z]	[29]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Vortioxetine.	Depression [6A70-6A7Z]	[29]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[27]
Miconazole	DMPMYE8	Major	Decreased metabolism of Glibenclamide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[29]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[29]
Sulfinpyrazone	DMEV954	Moderate	Decreased renal excretion of Glibenclamide caused by Sulfinpyrazone.	Gout [FA25]	[28]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Glibenclamide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Glibenclamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[37]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Glibenclamide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[40]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Glibenclamide caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[41]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[29]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[29]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Captopril.	Hypertension [BA00-BA04]	[29]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[27]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[29]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Glibenclamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[31]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[29]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Sulphadoxine.	Malaria [1F40-1F45]	[29]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[29]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[31]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Glibenclamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[42]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Safinamide.	Parkinsonism [8A00]	[29]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Rasagiline.	Parkinsonism [8A00]	[29]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Glibenclamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[43]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Glibenclamide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[44]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[29]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Glibenclamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[45]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[28]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Salsalate.	Rheumatoid arthritis [FA20]	[29]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Glibenclamide caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[46]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Glibenclamide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[31]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[29]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[29]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Glibenclamide due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[47]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[29]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Glibenclamide and Olsalazine.	Ulcerative colitis [DD71]	[29]
-----------


⏷ Show the Full List of 53 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Glyburide 6 mg tablet	6 mg	Oral Tablet	Oral
Glyburide 3 mg tablet	3 mg	Oral Tablet	Oral
Glyburide 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Glyburide 5 mg tablet	5 mg	Oral Tablet	Oral
Glyburide 1.5 mg tablet	1.5 mg	Oral Tablet	Oral
Glyburide 1.25 mg tablet	1.25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2414).
2	Spectroscopic interactions of non-insulin-dependent diabetes mellitus with levocetirizine. Pak J Pharm Sci. 2021 Jul;34(4(Supplementary)):1639-1644.
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1996 May;30(5):472-5. doi: 10.1177/106002809603000507.
5	BDDCS applied to over 900 drugs
6	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7	FDA Approved Drug Products: Glynase (Glyburide) Oral Tablets
8	Silberstein SD, McCrory DC: Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache. 2001 Nov-Dec;41(10):953-67.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13	Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
14	Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
15	Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
16	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17	Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
18	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
19	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
20	Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3193-7. doi: 10.1016/j.jchromb.2010.09.033. Epub 2010 Oct 23.
21	Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
22	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23	The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24.
24	Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18(1):16-22.
25	A potential role of calpains in sulfonylureas (SUs) -mediated death of human pancreatic cancer cells (1.2B4). Toxicol In Vitro. 2021 Jun;73:105128. doi: 10.1016/j.tiv.2021.105128. Epub 2021 Feb 27.
26	Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
27	Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
30	Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
31	Cerner Multum, Inc. "Australian Product Information.".
32	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
33	Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
34	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
35	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
36	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
37	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
38	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
39	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
40	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
41	Appel S, Rufenacht T, Kalafsky G, et al. "Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus." Am J Cardiol 76 (1995): a29-32. [PMID: 7604792]
42	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
43	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
45	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
46	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
47	Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]